NCT03211962|Completed
Can Urinary Concentrations of TIMP2 and IGFBP7 be Used to Predict Early Acute Renal Failure Following Cardiac Arrest?
ACR-CHECK
Loading search results
ACR-CHECK
Sponsor study identifier
observational
77
1 country
1
Study Start
February 1, 2017
Actual (reported)Primary Completion
March 1, 2019
Actual (reported)Study Completion
March 1, 2019
Actual (reported)Transient renal insufficiency is frequently observed in the course of cardiovascular arrest. Although elevation of creatinine is reversible in a large majority of cases, severe renal insufficiency is sometimes observed and is associated with a dark prognosis. Any intervention that may limit the worsening of renal function may have an impact on patient mortality. There is currently no validated pharmacological treatment to limit the progression of ARI or to accelerate its recovery. A major challenge then concerns the detection of the reversible character of renal damage. Renal biomarkers have been little studied in the prediction of severe ARI and mortality after cardiac arrest. The combination of TIMP2 (tissue inhibitor of metalloproteinase) and insulin-like growth factor binding protein (IGFBP7) in urine showed good diagnostic performance in the early detection of the risk of developing acute renal failure within 12 hours. Measured in the urine, the excretion of these two markers specifically reflects renal tubular lesions. Moreover, their rate seems to be strongly correlated with the severity of the tubular lesions. Thus, it can be reasonably assumed that their very early dosing in post-cardiac arrest could detect the presence and severity of renal tubular lesions. A threshold to be defined would discriminate patients at risk of developing an ARI within 48 hours post ACR and to distinguish between severe transient and severe persistent lesions beyond 72 hours.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1, 2017
Actual (reported)July 6, 2017
Actual (reported)July 11, 2017
Actual (reported)March 1, 2019
Actual (reported)March 1, 2019
Actual (reported)Analysis of the predictive value of the urinary concentration of TIMP2-IGFBP7
Analysis of the predictive value of the urinary concentration of TIMP2-IGFBP7 in the development of acute renal insufficiency defined by the KDIGO 3 stage within 48 hours after inclusion
Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients admitted to resuscitation in the aftermath of cardiac arrest with renal failure
CHU Amiens Picardie
Amiens, Picardie, 80054, France
77 participants (actual enrollment reported by the registry).
First Submitted
July 6, 2017
First Posted
July 11, 2017
Study Start
February 1, 2017
Actual (reported)The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure
Contact the study team to confirm eligibility.
Primary Completion
March 1, 2019
Actual (reported)Study Completion
March 1, 2019
Actual (reported)Last Updated
July 20, 2020
Record last verified: 2020-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: